Ab Tau ✓ Avoids T-cell response observed in other vaccines Rare Peripheral Amyloid Diseases PATHOGENIC PATHWAY Protein Misfolding KIDNEY Proteinuria Kidney failure SOLUBLE AGGREGATES AMYLOID FIBRILS CLONAL PLASMA CELLS INVOLVED IMMUNOGLOBU LIN LIGHT CHAIN HEART Restrictive cardiomyopathy Heart failure The four stages (Mayo Stages I–IV) of AL amyloidosis: life expectancy decreases as the disease progresses4,5 1 American Cancer Society. Available from: https://www.cancer.org/cancer/multiple-myeloma/treating/c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from to Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) ______________________________________ Ireland 98-1111119 (State or other jurisdiction of incorporation or ...

Global Neuroscience Collaboration with Bristol Myers Squibb – This propagation of pathology is thought to be mediated by tau "seeds" containing the MTBR of tau2 • Phase 1 SAD data in HVs demonstrated dose-proportional PRX005 concentrations in plasma with robust CNS penetration and generally safe and well tolerated 1Ahmed, Z., Cooper, J.. et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proxim ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Eric Endicott - Senior Vice President, Corporate Affairs and Communications Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Medical Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Wagner Zago - Chief Scientific Officer Conference Call Participants Michael Yee - Jefferies Neena Bitritto-Garg - Citi Charles Duncan - Cantor Fitzgerald Jay O ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 001-35676 ______________________________________ Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PROTHENA CORPORATION PUBLIC LIMITED ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMP ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COM ...

Corporate Overview March 2022 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things, the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery, preclinical, and clinical pipeline, and expected milestones in 2022 and beyond; our goal to continue building a biology-directed engine targeting protein dysregulation and to change the Alzheimer's disease treatment paradigm; the trea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATIO ...